The repeated headline on conflicting fair value signals and strong price momentum persists, with oral nicotine offering growth potential but not yet materializing. Technicals remain range-bound while fundamentals await clearer catalysts.

Sentiment remains mixed as dividend and defensive narratives compete with growth speculation around oral nicotine. No new trend-breaking headlines suggest continued market indecision.

Geopolitical risk headlines and valuation debates reinforce caution despite dividend stability. Long-term outlook depends on successful smoke-free transition, which remains uncertain.

Previous bullish signal from March 2 has not been reinforced by new technical data in these headlines. Price momentum meets conflicting signals, maintaining neutral positioning.